Search Results
Jun 23, 2025, 12:50 ET Bastion Fiduciary Launches New Industrial and Infrastructure Portfolio
For additional information about Bastion Fiduciary, including fees and services, please contact us or refer to our Form ADV Part 2A Brochure and Form CRS available on the SEC's Investment Adviser Public Disclosure website.
More news about: Bastion Fiduciary
Jun 22, 2025, 22:01 ET IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
or T2 hyperintense lesions were found in all patients.Safety: All patients experienced transient grade 1 CRS. No ICANS or other neurologic toxic effects were observed post infusion.All grade ≥3 cytopenias occurred within 30 days after CAR-T infusion.
More news about: IASO Bio
Jun 22, 2025, 20:03 ET Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
incorporating dual anti-BCMA binding sites for enhanced cell targeting and monovalent-optimized CD3 activity to minimize cytokine release syndrome (CRS), HBM7020 has demonstrated potent cytotoxicity with broad therapeutic potential in both immunological and oncological diseases. In August
More news about: Harbour BioMed
Jun 20, 2025, 17:00 ET NAMI Elects New Board Leadership to Advance National Mental Health Priorities
CAMHFA – Peer Leadership Council Elected DirectorContinuing Board Members (Term ending 2027) Ray Lay, CHW/CRS (Indiana)Glenda Wrenn Gordon, M.D., MSHP (Georgia)Babu George
More news about: National Alliance on Mental Illness (NAMI)
Jun 19, 2025, 17:31 ET Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline | DelveInsight
heterogeneity of DLL3 expression among patient populations, potential for resistance mechanisms, and safety concerns, especially cytokine release syndrome (CRS) in immune-engaging therapies, are critical issues under active investigation. Additionally, biomarker-based patient selection strategies are
More news about: DelveInsight Business Research, LLP
Jun 19, 2025, 03:48 ET AlphaGrep Receives In-Principle Approval from SEBI to Sponsor Mutual Fund
2010, AlphaGrep has built a specialised quant trading and investment platform. AlphaGrep manages more than Rs 8500 crs globally. Founded on the principles of transparency, discipline, and research-led decision making, AGIM has established itself as a pioneer in
More news about: AlphaGrep Securities
Jun 17, 2025, 08:30 ET Dominari Securities Serves as Exclusive Placement Agent to SRM Entertainment on a $100 Million Equity Investment
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Jun 16, 2025, 09:00 ET AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
of 48-m OS rate are 65.4% for all patients and 66.7% for LBCL patients, respectivelySafety Highlights: CRS of any grade: 93.8% | Grade ≥3: 2.1%ICANS of any grade: 6.3% | No severe cases (Grade ≥3) reportedNo new safety signals
More news about: AbelZeta Pharma, Inc.
Jun 15, 2025, 23:32 ET Keymed Biosciences annonce les derniers résultats d'un essai clinique évaluant CM336 publiés dans le New England Journal of Medicine
que les deux patients sont restés en rémission soutenue sans thérapies immunosuppressives ni transfusions. Aucun syndrome de libération de cytokines (CRS), syndrome de neurotoxicité associé aux cellules effectrices immunitaires (ICANS) ou infection n'est survenu pendant toute la durée du traitement et
More news about: Keymed Biosciences
Jun 15, 2025, 03:15 ET Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Jun 14, 2025, 21:58 ET Keymed Biosciences gibt die neuesten Ergebnisse der klinischen Studie mit CM336 bekannt, die im New England Journal of Medicine veröffentlicht wurden
Transfusionen in einer anhaltenden Remission waren. Während des gesamten Behandlungs- und Nachbeobachtungszeitraums traten weder ein Zytokinfreisetzungssyndrom (CRS) noch ein Immuneffektorzellen-assoziiertes Neurotoxizitätssyndrom (ICANS) oder Infektionsereignisse auf. Die Gesamtstudie zeigte, dass CM336 bei
More news about: Keymed Biosciences
Jun 13, 2025, 05:42 ET Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period.
More news about: Keymed Biosciences
Jun 13, 2025, 05:02 ET Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period.
More news about: Keymed Biosciences
Jun 12, 2025, 08:00 ET Ouro Medicines Announces a Clinical Trial of OM336 for Autoimmune Cytopenias Following Positive Case Reports in The New England Journal of Medicine
in recent and ongoing registrational studies in AIHA. No blood transfusions were administered, and there were no events of Cytokine Release Syndrome (CRS), Immune-Effector Cell-Associated Neurotoxicity Syndrome (ICANS), or infection. AIHA and ITP are among the most common types of autoimmune cytopenias,
More news about: Ouro Medicines
Jun 12, 2025, 06:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
(7.3%)In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observedIn the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one
More news about: ADC Therapeutics SA
Jun 10, 2025, 06:00 ET Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
provides a comprehensive "4C" business model for innovative biologics, combining differentiated CRO, integrated CDO, collaborative CPO, and specialized CRS. The company has built a global marketing network and established business with over 1,200 pharmaceutical and biotech companies worldwide. It has completed
More news about: Sanyou Bio
Jun 09, 2025, 02:46 ET 耶穌基督後期聖徒教會加強全球努力，將最初的捐贈預算翻倍，幫助改善全球超過 2,100 萬名婦女和兒童的生活
間醫療機構接受了追蹤營養不良臨床病例並提供治療的訓練。教會扮演領導角色，召集八間全球公認的非牟利組織，並成為四間團體的一員：每間團體都專注於造福婦女與兒童的項目。這些組織是：國際關懷協會 (CARE International)、天主教救濟會 (Catholic Relief Services; CRS)、Helen Keller Intl、iDE、MAP International、救助兒童會 (Save the Children)、飢餓計劃 (The Hunger Project) 和 Vitamin Angels。 四個組別及其重點和目標如下 Group
More news about: The Church of Jesus Christ of Latter-day Saints
Jun 07, 2025, 14:14 ET 耶稣基督的教会加强全球努力，将最初的预测增加一倍，帮助改善全球2100多万妇女和儿童的生活
受了跟踪营养不良临床病例和提供治疗的培训。教会在召集八个全球公认的非营利组织方面发挥了领导作用，作为四个小组的一部分，每个小组都专注于造福妇女和儿童的项目。 这些组织包括： CARE International、Catholic Relief Services (CRS)、Helen Keller Intl、iDE、MAP International、Save the Children、The Hunger Project和Vitamin Angels。 四个小组及其重点领域和目标如下 第1组
More news about: The Church of Jesus Christ of Latter-day Saints
Jun 07, 2025, 14:07 ET La Iglesia de Jesucristo fortalece el esfuerzo global, duplicando las proyecciones iniciales, ayudando a mejorar las vidas de más de 21 millones de mujeres y niños en todo el mundo
cuatro grupos, cada uno enfocado en proyectos que benefician a mujeres y niños. Estas organizaciones son: CARE International, Catholic Relief Services (CRS), Helen Keller Intl, iDE, MAP International, Save the Children, The Hunger Project y Vitamin Angels. Los cuatro
More news about: The Church of Jesus Christ of Latter-day Saints
Jun 07, 2025, 00:00 ET The Church of Jesus Christ strengthens global effort, doubling initial projections, helping improve the lives of more than 21 million women and children worldwide
part of four groups, each focused on projects benefiting women and children. These organizations are: CARE International, Catholic Relief Services (CRS), Helen Keller Intl, iDE, MAP International, Save the Children, The Hunger Project, and Vitamin Angels. The four
More news about: The Church of Jesus Christ of Latter-day Saints
Jun 04, 2025, 10:40 ET Bastion Fiduciary Launches New Energy ETF (CBOE: BESF)
For additional information about Bastion Fiduciary, including fees and services, please contact us or refer to our Form ADV Part 2A Brochure and Form CRS available on the SEC's Investment Adviser Public Disclosure website.
More news about: Bastion Fiduciary
Jun 04, 2025, 02:56 ET Vollständige Daten zur Dosiseskalation zeigen anhaltend hohe Ansprechraten und ein günstiges Sicherheitsprofil von ISB 2001, einem ersten trispezifischen Antikörper gegen BCMA × CD38 × CD3, zur Behandlung von rezidiviertem/refraktärem multiplem Myelom
dosislimitierenden Toxizitäten (DLTs) berichtet wurden. Das Zytokinfreisetzungssyndrom (CRS) trat bei 24 Patienten (69 %) auf, in erster Linie in der Stufe 1, und nur bei vier Patienten traten Ereignisse der Stufe 2 auf. CRS war meist auf die erste Verabreichung von ISB 2001 beschränkt, und es wurden keine
More news about: Ichnos Glenmark Innovation
Jun 03, 2025, 10:45 ET Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
life-threatening, occurred following treatment with CARVYKTI®, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with CARVYKTI®. Provide
More news about: Johnson & Johnson
Jun 03, 2025, 10:45 ET Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
based on the needs of their patients with relapsed or refractory multiple myeloma." The most common adverse event was cytokine release syndrome (CRS), occurring in 59 percent of patients, but no events were Grade 3 or higher. Twenty-eight percent of patients experienced Grade 3 or higher infections.
More news about: Johnson & Johnson
Jun 02, 2025, 13:46 ET Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported. Cytokine release syndrome (CRS) occurred in 24 patients (69%), primarily Grade 1, with only four patients experiencing Grade 2 events. CRS was mostly limited to the first administration of ISB 2001, and no severe or life-threatening
More news about: Ichnos Glenmark Innovation